Parexel creates committee to boost business in biopharmaceuticals

Parexel International, a global biopharmaceutical services provider, has appointed four of its executives to its Business Review Committee, a senior leadership team.

The employees being appointed are David Godwin, senior vice president of global business development; Michelle Graham, senior vice president and chief human resources officer; Sy Pretorius, MD, senior vice president and chief scientific officer; and Joshua Schultz, senior vice president and worldwide head of Parexel Access.

The Business Review Committee will focus on boosting business from adjacent biopharmaceutical markets for the company that employs more than 18,000 people, the company said in a statement.

Each team member will continue to perform the duties in existing positions in addition to individual responsibilities for the committee.

Parexel, headquartered in Boston, provides a range of expertise-based clinical research, consulting, medical communications and technology solutions and services to pharmaceutical, biotechnology and medical device industries.

“Parexel has a history of growth, innovation and leadership that spans more than 30 years, and these leaders have played an important role in our success,” said Josef von Rickenbach, chairman and CEO of Parexel, in a statement. “We will leverage the expertise of these senior leaders to implement our strategic objectives and further transform Parexel, positioning the company for future growth.”